Characteristics of the cytokine profile in patients with a new coronavirus infection with chronic hepatitis C

Cover Page

Cite item

Full Text

Abstract

Aim – to assess individual cytokine profile parameters in patients with new coronavirus infection combined with chronic hepatitis C (CHC), depending on the severity of COVID-19 and liver fibrosis.

Material and methods. A comparative study involved 147 patients, whose laboratory and instrumental examination data was analyzed. The first group included patients with COVID-19 and CHC; the second group consisted of 81 patients with COVID-19, and the third group included 94 patients with CHC. The patients in the first and second groups were divided into subgroups based on the severity of COVID-19, as well as the degree of liver fibrosis.

Results. It was established that in 73% of patients with a concurrent COVID-19 infection and CHC, the levels of several cytokines during the height of COVID-19 disease were higher than in CHC patients without COVID-19. The values of certain cytokines significantly differed from those of patients with COVID-19, regardless of the severity of the disease. It was also noted that in CHC patients with severe COVID-19 progression, the levels of certain cytokines were higher than in patients with COVID-19 alone. In the group of patients with concurrent COVID-19 and CHC, an increase in the values of certain cytokines was observed as liver fibrosis progressed.

About the authors

Elizaveta I. Temnik

Samara State Medical University

Email: elizabeth_temnik@outlook.com
ORCID iD: 0000-0002-4283-1481

assistant of the Department of Infectious Diseases with Epidemiology

Russian Federation, Samara

Dmitrii Yu. Konstantinov

Samara State Medical University

Email: d.u.konstantinov@samsmu.ru
ORCID iD: 0000-0002-6177-8487

PhD, Associate professor, Head of the Department of Infectious Diseases with Epidemiology

Russian Federation, Samara

Larisa L. Popova

Samara State Medical University

Author for correspondence.
Email: l.l.popova@samsmu.ru
ORCID iD: 0000-0003-0549-361X

PhD, Professor, Department of Infectious Diseases with Epidemiology

Russian Federation, Samara

References

  1. Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316-329. DOI: https://doi.org/10.7150/thno.49713
  2. Gorelov AV, Ploskireva AA, Muzyka AD. The evolution of the clinical and pathogenetic features of the coronavirus infection Covid-19. RMJ. Russian Medical Journal. 2022;6(11):626-634. [Горелов А.В., Плоскирева А.А., Музыка А.Д. Эволюция клинико-патогенетических особенностей коронавирусной инфекции COVID-19. РМЖ. Медицинское обозрение. 2022;6(11):626-634]. DOI: https://doi.org/10.32364/2587-6821-2022-6-11-626-634
  3. Demina IA, Komarova AG, Il'ina MV, et al. Clinical features of coronavirus infection COVID-19 in patients with arterial hypertension. Lechashchii vrach. 2022;4:54-59. (In Russ.). [Демина И.А., Комарова А.Г., Ильина М.В., и др. Клинические особенности коронавирусной инфекции COVID-19 у пациентов с артериальной гипертензией. Лечащий врач. 2022;4:54-59]. DOI: https://doi.org/10.51793/OS.2022.25.4.010
  4. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. DOI: https://doi.org/10.1001/jama.2020.2648
  5. Zhou X, Ye Q. Cellular Immune Response to COVID-19 and Potential Immune Modulators. Frontiers in Immunology. 2021;12. DOI: https://doi.org/10.3389/fimmu.2021.646333
  6. Gonik MI, Bueverova EL, Bueverov AO. Hyperferritinemia, chronic hepatitis C and COVID-19: what do they have in common? Medical Council. 2023;17(8):150-157. [Гоник М.И., Буеверова Е.Л., Буеверов А.О. Гиперферритинемия, хронический гепатит С и COVID-19: что общего? Медицинский совет. 2023;17(8):150-157]. DOI: https://doi.org/10.21518/ms2023-142
  7. Han Z, Huang T, Deng Y, et al. Expression profile and kinetics of cytokines and chemokines in patients with chronic hepatitis C. Int J Clin Exp Med. 2015;8:17995-18003. PMID: 26770394
  8. León FJF, da Silva LL, Santos AC et al. Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus. J Med Virol. 2022;94:2296-2301. DOI: https://doi.org/10.1002/jmv.27614
  9. Ronderos D, Omar AMS, Abbas H, et al. Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality. World J Clin Cases. 2021;9(29):8749-8762. DOI: https://doi.org/10.12998/wjcc.v9.i29.8749
  10. Bucurica S, Ionita Radu F, Bucurica A, et al. Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditions – Review of the Literature. Medicina. 2023;59:62. DOI: https://doi.org/10.3390/medicina59010062
  11. Shirley K, Loftis JM. A spotlight on HCV and SARS-CoV-2 co-infection and brain function. Pharmacol Biochem Behav. 2022;217:173403. DOI: https://doi.org/10.1016/j.pbb.2022.173403
  12. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181(5):1036-1045.e9. DOI: https://doi.org/10.1016/j.cell.2020.04.026
  13. Ferreira J, Oliveira M, Bicho M, et al. Role of Inflammatory/Immune Response and Cytokine Polymorphisms in the Severity of Chronic Hepatitis C (CHC) before and after Direct Acting Antiviral (DAAs) Treatment. Int J Mol Sci. 2023;24(2):1380. DOI: https://doi.org/10.3390/ijms24021380
  14. Chen X, Liu X, Duan S, et al. Plasma Inflammatory Biomarkers Associated with Advanced Liver Fibrosis in HIV-HCV-Coinfected Individuals. Int J Environ Res Public Health. 2020;17(24):9474. DOI: https://doi.org/10.3390/ijerph17249474
  15. Konstantinov DYu, Popova LL, Konstantinova E.A. Modern aspects of HCV infection. Serum cytokine system in the treatment of chronic hepatitis. Samara, 2015. (In Russ.). [Константинов Д.Ю., Попова Л.Л., Константинова Е.А. Современные аспекты HCV-инфекции. Система сывороточных цитокинов при лечении хронического гепатита. Самара, 2015].
  16. Baskic D, Vukovic V, Popovic S, et al. Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution. PLoS ONE. 2019;14(7):e0219508. DOI: https://doi.org/10.1371/journal.pone.0219508
  17. Panova MS, Panchenko AS. The role of cytokines and their genetic polymorphism in the development of hypoxic-ischemic encephalopathy among full-term newborn children. Pediatrician. 2017;8(6):99-104. [Панова М.С., Панченко А.С. Роль цитокинов и их генетического полиморфизма в развитии гипоксически-ишемической энцефалопатии у доношенных новорожденных детей. Педиатр. 2017;8(6):99-104]. DOI: https://doi.org/10.17816/PED8699-104

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Temnik E.I., Konstantinov D.Y., Popova L.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).